Synthetic disulfide‐bridged cyclic peptides mimic the anti‐angiogenic actions of chondromodulin‐I
Authors:
Open Access
- 20 March 2012
- journal article
- research article
- Published by Wiley in Cancer Science
- Vol. 103 (7) , 1311-1318
Abstract
Chondromodulin‐I (ChM‐I) is a 25‐kDa glycoprotein in cartilage matrix that inhibits angiogenesis. It contains two distinctive structural domains: the N‐terminal third of the molecule is a hydrophilic domain that contains O‐linked and N‐linked oligosaccharide chains, and the C‐terminal two‐thirds is a hydrophobic domain that contains all of the cysteine residues. In the present study, we have attempted to further uncover the structural requirements for ChM‐I to exert anti‐angiogenic activity by monitoring its inhibition of the vascular endothelial growth factor (VEGF)‐A‐induced migration of HUVEC in vitro. Site‐directed mutagenesis experiments revealed that the cyclic structure formed by the disulfide bridge between Cys83 and Cys99 in human ChM‐I is indispensable for its anti‐angiogenic function. Moreover, the C‐terminal hydrophobic tail (from Trp111 to Val120) was found to play an important role in ensuring the effectiveness of ChM‐I activity on HUVEC. A synthetic cyclic peptide corresponding to the ChM‐I region between Ile82 to Arg100 also inhibited the migration of HUVEC, while replacing the Cys83 and Cys99 residues in this peptide with Ser completely negated this inhibitory activity. An additional synthetic cyclic peptide harboring the hydrophobic C‐terminal tail of ChM‐I clearly mimicked the inhibitory action of this protein on the migration of HUVEC and successfully inhibited tumor angiogenesis and growth in a xenograft mouse model of human chondrosarcoma. (Cancer Sci 2012; 103: 1311–1318)Keywords
This publication has 32 references indexed in Scilit:
- A functional role of the glycosylated N-terminal domain of chondromodulin-IJournal of Bone and Mineral Metabolism, 2010
- Impairment of VEGF-A-stimulated lamellipodial extensions and motility of vascular endothelial cells by chondromodulin-I, a cartilage-derived angiogenesis inhibitorExperimental Cell Research, 2010
- Chondromodulin-I maintains cardiac valvular function by preventing angiogenesisNature Medicine, 2006
- Anti-angiogenic action of the C-terminal domain of tenomodulin that shares homology with chondromodulin-IJournal of Cell Science, 2004
- Localization and expression of chondromodulin-I in the rat corneaArchives of Histology and Cytology, 2003
- Disabling ErbB Receptors with Rationally Designed Exocyclic Mimetics of Antibodies: Structure−Function AnalysisJournal of Medicinal Chemistry, 2001
- A novel gene, tendin, is strongly expressed in tendons and ligaments and shows high homology with chondromodulin‐IDevelopmental Dynamics, 2001
- Molecular Cloning of tenomodulin, a Novel Chondromodulin-I Related GeneBiochemical and Biophysical Research Communications, 2001
- Efficient selection for high-expression transfectants with a novel eukaryotic vectorGene, 1991
- Molecular cloning of a new class of cartilage-specific matrix, chondromodulin-I, which stimulates growth of cultured chondrocytesBiochemical and Biophysical Research Communications, 1991